RecruitingNon-small Cell Lung Cancer Stage IIICNon-small Cell Lung Cancer Stage IVNon Small Cell Lung Cancer
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.
Sponsor: University of California, Davis
You may qualify if…
- ✓ Participants must have histologically confirmed non-small cell lung cancer that is metastatic or unresectable (stage IIIC or IV), deemed appropriate to receive standard of care immune checkpoint inhibitor-based therapy given with palliative intent.
- ✓ Age ≥18 years at the time of consent.
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥50%).
- ✓ Ability to understand and willingness to sign the informed consent form (ICF).
- ✓ Stated ability and willingness to adhere to all protocol requirements while on study
You may not qualify if…
- ✕ Tumor with known sensitizing alteration in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1.
- ✕ Medical comorbidities precluding immune checkpoint inhibitor-based therapy per treating investgator's discretion.
- ✕ Previous systemic therapy for metastatic Stage IIIC or IV NSCLC. Patients who previously completed systemic therapy for early stage or locally advanced NSCLC ≥ 80 days prior to trial registration are eligible for inclusion.
- ✕ Any condition that in the opinion of the investigator would interfere with the participant's safety or compliance while on study
Where it's recruiting
California
Chico · Marysville · Sacramento · Truckee
Source: ClinicalTrials.gov · NCT07250477 · last updated 2026-08-25